Unite for authorization of Masitinib in ALS

0 a signé. Allez jusqu'à 1 500 !


We - patients, families and caretakers of patients - would like to address the following message to respective national Health Authorities throughout the world.
Amyotrophic Lateral Sclerosis is a devastating neurodegenerative disease that triggers upper and lower motor neuron loss and that rapidly affects vital functions, with a somber diagnostic short-to-medium term. All patients and relatives badly know about it and experience it.
Unadressed medical needs in ALS are huge, as important as in certain cancers.
Several scientific publications and statements recently expressed the fact that Masitinib might be an efficient medical compound in ALS, an hypothesis publicly relayed by key opinion leaders a.o in scientific publications and congresses. Experts talk about Masitinib potential efficacy, with an overall acceptable toxicity degree compared to the dreadful perspectives of the disease.
Patients have simply waited for too long for decades. We really call upon and urge respective national Health Authorities to act now. Should they consider that Masitinib might represent a chance to ALS patients, respective National Health Authorities should authorize without delay Masitinib in Amyothrophic Lateral Sclerosis. We do sincerely urge you to UNITE, NOT to keep silent and NOT to simply leave aside an opportunity that could end up being “THE ONE missed".

Thanks for joining forces and sign NOW



Alspatients compte sur vous aujourd'hui

Alspatients TOGETHER a besoin de votre aide pour sa pétition “alspatients2gether@gmail.com: Unite for authorization of Masitinib in ALS”. Rejoignez Alspatients et 1 099 signataires.